Drug Trial Radar · NCT02587065
Plegridy Satisfaction Study in Participants
Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
193
Actual
Start
Feb 3, 2016
Primary completion
Oct 2, 2017
Study completion Dec 21, 2017
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Oct 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction Questionnaire to Medication (TSQM-9), at 12 weeks. The secondary objectives of this study are to evaluate in this study population: effects of Peg-IFN beta-1a treatment on participants' satisfaction at 24 weeks; effects of Peg-IFN beta-1a treatment on short-term participants' adherence; effects of Peg-IFN beta-1a treatment on participants' fatigue; effects of Peg-IFN beta-1a on disease activity and physical disability; impact of Peg-IFN beta-1a treatment on participant-reported health-related quality of life; impact of Peg-IFN beta-1a treatment on participants' injection-system satisfaction; Evaluate the relationship between participants' satisfaction and adherence; Evaluate the relationship between participants' satisfaction and social-demographic factors (age, sex, employment working, level of education, etc) and clinical characteristics (annualized relapse rate \[ARR\], disability, etc.) and to evaluate the treatment safety and tolerability.
Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
peginterferon beta-1aDrug
125 mcg administered subcutaneously (SC) every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12Time frame: Baseline, Week 12
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Arezzo, Italy
Research Site
Bari, Italy
Research Site
Cagliari, Italy
Research Site
Cefalù, Italy
Research Site
Chieti, Italy
Research Site
Como, Italy
Research Site
Fidenza, Italy
Research Site
Foligno, Italy
Research Site
Gallarate, Italy
Research Site
Genova, Italy
Research Site
L’Aquila, Italy
Research Site
Messina, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Modena, Italy
Research Site
Mondovì, Italy
research Site
Naples, Italy
Research Site
Naples, Italy
Research Site
Orbassano, Italy
Research Site
Ozieri, Italy
Research Site
Palermo, Italy
Research Site
Palermo, Italy
Research Site
Pavia, Italy
Research Site
Pietra Ligure, Italy
Research Site
Pozzilli, Italy
Research Site
Reggio Calabria, Italy
Research Site
Roma, Italy
Research Site
Roma, Italy
Research Site
Roma, Italy
Research Site
Torino, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.